Published: 2026-02-10
Status:
Analyzed
Predictions from this Video
Incorrect: 0
Prediction
Topic
Status
Yatharth Hospital stock price is predicted to find strong support between ₹485 and ₹55.
"The zone of 485 to 55 can act as a strong support for the stock."
Pending
Yatharth Hospital management predicts approximately 30% year-on-year revenue growth for FY26.
"the management has given guidance of around 30% year-on-year revenue growth for this year."
Pending
Yatharth Hospital's mature hospitals are projected to achieve 28.5% to 29% EBITDA margins in the long term with improved occupancy.
"In the long term, mature hospitals have the potential to generate 28.5 to 29% EBITDA margins as occupancy improves."
Pending
Yatharth Hospital aims to double its bed capacity from 2,500 beds within the next 3-4 years.
"the management has set a target to double the capacity from 2,500 beds in the next three to four years."
Pending
Yatharth Hospital targets 8-10% average revenue per occupied bed (ARPOB) growth on operational sites.
"ARPOB has a target of 8 to 10% growth on operational sites."
Pending
Agra Hospital's occupancy is predicted to increase from 35% to approximately 60% starting in FY27.
"we feel that the occupancy of 35% can reach around 60% from next year itself."
Pending
Yatharth Hospital plans a capital expenditure of ₹1,500 crore over the next 4.5 to 5 years.
"The company has also outlined a capex plan of Rs 1,500 crore for the next 4.5 to 5 years."
Pending
Yatharth Hospital's existing bed occupancy is expected to rise from 65% to approximately 70% within one year.
"we believe that the existing beds occupancy of 65% can go close to 70% within one year."
Pending
Great Eastern Shipping stock price is predicted to find strong support at ₹923 and ₹82.
"The levels of 923 and 82 can act as strong support zones for the stock."
Pending
Aurbindo Pharma stock price is predicted to find strong support between ₹960 and ₹1000.
"The zone of 960 to 1000 can act as a strong support for the stock."
Pending
Aurbindo Pharma management targets a 20-21% margin for FY26.
"the management has set a target of 20 to 21% margin for the financial year 26."
Pending
Aurbindo Pharma's European business is expected to exceed €1 billion in annual revenue by the end of FY26.
"The company's European business is on track to cross €1 billion in annual revenue by the end of FY26."
Pending
Aurbindo Pharma aims for its China facility's turnover to reach a triple-digit level within the next 2-3 years.
"the target has been set to take the turnover to triple digit level in the next two to three years."
Pending
Aurbindo Pharma plans for ongoing sustenance capital expenditure of approximately 150-200 million.
"we will be doing normal caps which will be somewhere around may be around 150 to 200 million which will be the sustenance capital which we will be increasing it"
Pending